论文部分内容阅读
目的观察胃癌组织中生长抑素（ＳＳ）表达与表皮生长因子受体（ＥＧＦＲ）表达的相互关系，探讨其抑癌的可能机制．方法应用免疫组化ＬＳＡＢ法及即用型ＳＰ法，对１４７例各种组织学类型胃癌中ＳＳ及ＥＧＦＲ的表达进行观察比较，并对其中１２７例患者进行预后随访．结果胃癌中ＳＳ阳性表达率为２５７％．ＥＧＦＲ阳性表达率５４３％．ＳＳ阳性及ＳＳ阴性两组胃癌ＥＧＦＲ的表达有明显差异（Ｐ＜００１）．ＳＳ阳性胃癌组ＥＧＦＲ的表达明显减少；ＳＳ阴性胃癌组ＥＧＦＲ的表达增多．ＳＳ阳性胃癌较ＳＳ阴性胃癌生存期长，预后好（Ｐ＜００１）．相反，ＥＧＦＲ阳性胃癌较ＥＧＦＲ阴性胃癌生存期短，预后差（Ｐ＜００１）．尤其是伴有ＳＳ阴性表达的ＥＧＦＲ阳性胃癌预后更差．结论ＳＳ及ＥＧＦＲ在人体胃癌组织中的表达有一定拮抗性．ＳＳ阴性的ＥＧＦＲ阳性胃癌预后更差．ＳＳ的抑癌机制之一可能是干扰了生长因子的合成，影响了细胞内调节细胞生长信号的传递，从而抑制肿瘤生长
Objective To observe the relationship between the expression of somatostatin (SS) and the expression of epidermal growth factor receptor (EGFR) in gastric cancer, and to explore the possible mechanism of tumor suppressor. Methods The expression of SS and EGFR in 147 cases of various histological types of gastric cancer were observed and compared using immunohistochemical LSAB method and ready-to-use SP method, and 127 of them were followed up. Results The positive expression rate of SS in gastric cancer was 257%. The positive rate of EGFR expression was 54. 3%. The expression of EGFR in gastric carcinoma was significantly different between SS positive and SS negative groups (P<001). The expression of EGFR in the SS positive gastric cancer group was significantly decreased. The expression of EGFR in the SS negative gastric cancer group was increased. SS-positive gastric cancer has a longer survival time and better prognosis than SS-negative gastric cancer (P<001). On the contrary, EGFR-positive gastric cancer had a shorter survival time and worse prognosis than EGFR-negative gastric cancer (P<001). In particular, EGFR-positive gastric cancer with SS negative expression has a worse prognosis. Conclusion The expression of SS and EGFR in human gastric cancer tissues is somewhat antagonistic. SS-negative EGFR-positive gastric cancer has a worse prognosis. One of the mechanisms of SS inhibition may be to interfere with the synthesis of growth factors, affect the regulation of cell growth signal transmission in cells, thereby inhibiting tumor growth.